D
Dev Banerjee
Researcher at Woolcock Institute of Medical Research
Publications - 29
Citations - 931
Dev Banerjee is an academic researcher from Woolcock Institute of Medical Research. The author has contributed to research in topics: Obstructive sleep apnea & Sleep apnea. The author has an hindex of 15, co-authored 24 publications receiving 849 citations. Previous affiliations of Dev Banerjee include University College Birmingham & National Health and Medical Research Council.
Papers
More filters
Journal ArticleDOI
Obesity hypoventilation syndrome: Hypoxemia during continuous positive airway pressure
TL;DR: In this paper, the effect of 1 night of continuous positive airway pressure (CPAP) on sleep architecture, AHI, arousal indexes, and nocturnal oxygenation was assessed.
Journal ArticleDOI
Effectiveness of lifestyle interventions on obstructive sleep apnea (OSA): systematic review and meta-analysis.
Marzieh Araghi,Yen-Fu Chen,Alison Jagielski,Sopna Choudhury,Dev Banerjee,Dev Banerjee,Dev Banerjee,Shakir Hussain,G. Neil Thomas,G. Neil Thomas,Shahrad Taheri +10 more
TL;DR: In this article, the authors conducted a systematic review and meta-analysis to assess the impact of weight loss through diet and physical activity on measures of OSA: apnea-hypopnea index (AHI) and oxygen desaturation index of 4% (ODI4).
Journal ArticleDOI
Treatment of obesity hypoventilation syndrome and serum leptin.
TL;DR: Regular NIV use reduces serum leptin in OHS and may be a modulator of respiratory drive in patients with OHS, suggesting that central leptin resistance may promote the development of OHS in humans.
Journal ArticleDOI
The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea
Brendon J. Yee,Craig L. Phillips,Craig L. Phillips,Dev Banerjee,Ian D. Caterson,Jan Hedner,Jan Hedner,Jan Hedner,Ronald R. Grunstein,Ronald R. Grunstein +9 more
TL;DR: Moderate (∼10%) weight loss with SIB-WL results in improvement in OSA severity without increase in blood pressure in closely monitored OSA subjects.
Journal ArticleDOI
Pharmacotherapy for excessive daytime sleepiness
TL;DR: Until adequately powered randomised-controlled trials confirm long-term efficacy and safety, the recommendation of wakefulness promoters in healthy adults cannot be justified.